{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T21:18:15Z","timestamp":1787951895367,"version":"build-2784847793"},"reference-count":74,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T00:00:00Z","timestamp":1786060800000},"content-version":"vor","delay-in-days":6,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100019018","name":"Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences","doi-asserted-by":"publisher","award":["2021-I2M-1-008"],"award-info":[{"award-number":["2021-I2M-1-008"]}],"id":[{"id":"10.13039\/501100019018","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005150","name":"Chinese Academy of Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005150","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","nmcd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nutrition, Metabolism and Cardiovascular Diseases"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.numecd.2026.104950","type":"journal-article","created":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T19:07:24Z","timestamp":1785697644000},"page":"104950","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Intensified lipid-lowering strategies and their effect on atherogenic and metabolic markers in coronary artery disease: a prospective cohort study"],"prefix":"10.1016","author":[{"given":"Lei","family":"Bao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Fan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Ning","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng-Ying","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Jia","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-Lu","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Jun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke-Fei","family":"Dou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1719-3369","authenticated-orcid":false,"given":"Na-Qiong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3_suppl","key":"10.1016\/j.numecd.2026.104950_bib1","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1177\/2047487317706586","article-title":"Coronary artery disease: risk stratification and patient selection for more aggressive secondary prevention","volume":"24","author":"Schiele","year":"2017","journal-title":"Eur J Prev Cardiol"},{"issue":"25","key":"10.1016\/j.numecd.2026.104950_bib2","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.1016\/j.jacc.2023.11.007","article-title":"Global burden of cardiovascular diseases and risks, 1990-2022","volume":"82","author":"Mensah","year":"2023","journal-title":"J Am Coll Cardiol"},{"issue":"15","key":"10.1016\/j.numecd.2026.104950_bib3","doi-asserted-by":"crossref","first-page":"4611","DOI":"10.3390\/jcm11154611","article-title":"Newer and emerging LDL-c lowering agents and implications for ASCVD residual risk","volume":"11","author":"Rikhi","year":"2022","journal-title":"J Clin Med"},{"issue":"16","key":"10.1016\/j.numecd.2026.104950_bib4","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1056\/NEJMra1806939","article-title":"Lipid management for the prevention of atherosclerotic cardiovascular disease","volume":"381","author":"Michos","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2026.104950_bib5","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehaf190","article-title":"2025 focused update of the 2019 ESC\/EAS guidelines for the management of dyslipidaemias","author":"Mach","year":"2025","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.numecd.2026.104950_bib6","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"issue":"25","key":"10.1016\/j.numecd.2026.104950_bib7","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American college of cardiology\/american heart association task force on clinical practice guidelines","volume":"139","author":"Grundy","year":"2019","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.numecd.2026.104950_bib8","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1210\/er.2018-00184","article-title":"The forgotten lipids: triglycerides, remnant cholesterol, and atherosclerotic cardiovascular disease risk","volume":"40","author":"Sandesara","year":"2019","journal-title":"Endocr Rev"},{"issue":"10","key":"10.1016\/j.numecd.2026.104950_bib9","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1093\/eurjpc\/zwad107","article-title":"Remnant cholesterol: a reliable prognostic marker?","volume":"31","author":"Pirillo","year":"2024","journal-title":"Eur J Prev Cardiol"},{"issue":"2","key":"10.1016\/j.numecd.2026.104950_bib10","doi-asserted-by":"crossref","DOI":"10.31083\/RCM25985","article-title":"Remnant cholesterol and residual risk of atherosclerotic cardiovascular disease","volume":"26","author":"Li","year":"2025","journal-title":"Rev Cardiovasc Med"},{"issue":"7","key":"10.1016\/j.numecd.2026.104950_bib11","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1001\/jamacardio.2022.0987","article-title":"Lipoprotein(a) and its significance in cardiovascular disease: a review","volume":"7","author":"Duarte","year":"2022","journal-title":"JAMA Cardiol"},{"issue":"10459","key":"10.1016\/j.numecd.2026.104950_bib12","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S0140-6736(24)01308-4","article-title":"Lipoprotein(a) and cardiovascular disease","volume":"404","author":"Nordestgaard","year":"2024","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.numecd.2026.104950_bib13","doi-asserted-by":"crossref","first-page":"256","DOI":"10.3390\/jcdd12070256","article-title":"The role of non-HDL cholesterol and apolipoprotein b in cardiovascular disease: a comprehensive review","volume":"12","author":"Katsi","year":"2025","journal-title":"J Cardiovasc Dev Dis"},{"issue":"12","key":"10.1016\/j.numecd.2026.104950_bib14","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1001\/jama.2012.366","article-title":"Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein b levels with risk of cardiovascular events among patients treated with statins: a meta-analysis","volume":"307","author":"Boekholdt","year":"2012","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.numecd.2026.104950_bib15","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.atherosclerosis.2015.04.810","article-title":"Non-HDL cholesterol goal attainment and its relationship with triglyceride concentrations among diabetic subjects with cardiovascular disease: a nationwide survey of 2674 individuals in Hungary","volume":"241","author":"Mark","year":"2015","journal-title":"Atherosclerosis"},{"issue":"15","key":"10.1016\/j.numecd.2026.104950_bib16","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1177\/2047487320905185","article-title":"Triglyceride concentrations and non-high-density lipoprotein cholesterol goal attainment in the ODYSSEY phase 3 trials with alirocumab","volume":"27","author":"Vallejo-Vaz","year":"2020","journal-title":"Eur J Prev Cardiol"},{"issue":"3","key":"10.1016\/j.numecd.2026.104950_bib17","doi-asserted-by":"crossref","DOI":"10.1177\/03000605231164548","article-title":"Insulin resistance and cardiovascular disease","volume":"51","author":"Kosmas","year":"2023","journal-title":"J Int Med Res"},{"issue":"1","key":"10.1016\/j.numecd.2026.104950_bib18","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1186\/s12933-023-01898-1","article-title":"Association between non-insulin-based insulin resistance indices and cardiovascular events in patients undergoing percutaneous coronary intervention: a retrospective study","volume":"22","author":"Zhang","year":"2023","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"10.1016\/j.numecd.2026.104950_bib19","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s12933-024-02159-5","article-title":"Insulin resistance and coronary inflammation in patients with coronary artery disease: a cross-sectional study","volume":"23","author":"Yang","year":"2024","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"10.1016\/j.numecd.2026.104950_bib20","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s12933-024-02163-9","article-title":"Associations of the triglyceride-glucose index and atherogenic index of plasma with the severity of new-onset coronary artery disease in different glucose metabolic states","volume":"23","author":"Wu","year":"2024","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"10.1016\/j.numecd.2026.104950_bib21","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/s12933-023-01886-5","article-title":"Non-linear association of atherogenic index of plasma with insulin resistance and type 2 diabetes: a cross-sectional study","volume":"22","author":"Yin","year":"2023","journal-title":"Cardiovasc Diabetol"},{"issue":"16","key":"10.1016\/j.numecd.2026.104950_bib22","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1161\/CIRCULATIONAHA.106.635011","article-title":"Defining obesity cut points in a multiethnic population","volume":"115","author":"Razak","year":"2007","journal-title":"Circulation"},{"issue":"25","key":"10.1016\/j.numecd.2026.104950_bib23","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1093\/eurheartj\/ehad371","article-title":"Lipid distributions in the global diagnostics network across five continents","volume":"44","author":"Martin","year":"2023","journal-title":"Eur Heart J"},{"issue":"9","key":"10.1016\/j.numecd.2026.104950_bib24","doi-asserted-by":"crossref","first-page":"621","DOI":"10.26599\/1671-5411.2023.09.008","article-title":"China guidelines for lipid management","volume":"20","author":"Li","year":"2023","journal-title":"J Geriatr Cardiol"},{"issue":"7","key":"10.1016\/j.numecd.2026.104950_bib25","doi-asserted-by":"crossref","first-page":"3347","DOI":"10.1210\/jc.2010-0288","article-title":"The product of triglycerides and glucose, a simple measure of insulin sensitivity. Comparison with the euglycemic-hyperinsulinemic clamp","volume":"95","author":"Guerrero-Romero","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.numecd.2026.104950_bib26","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jacl.2010.02.005","article-title":"\u201catherogenic index of plasma\u201d (log10 triglyceride\/high-density lipoprotein\u2212cholesterol) predicts high blood pressure, diabetes, and vascular events","volume":"4","author":"Onat","year":"2010","journal-title":"J Clin Lipidol"},{"issue":"16","key":"10.1016\/j.numecd.2026.104950_bib27","doi-asserted-by":"crossref","first-page":"4600","DOI":"10.3390\/jcm13164600","article-title":"Clinical updates in coronary artery disease: a comprehensive review","volume":"13","author":"Bottardi","year":"2024","journal-title":"J Clin Med"},{"issue":"13","key":"10.1016\/j.numecd.2026.104950_bib28","article-title":"ACC\/AHA\/ACEP\/NAEMSP\/SCAI guideline for the management of patients with acute coronary syndromes: a report of the American college of cardiology\/american heart association joint committee on clinical practice guidelines","volume":"151","author":"Rao","year":"2025","journal-title":"Circulation"},{"issue":"Supplement_1","key":"10.1016\/j.numecd.2026.104950_bib29","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.2337\/dc24-S002","article-title":"2. Diagnosis and classification of diabetes:standards of care in diabetes\u20142024","volume":"47","author":"Elsayed","year":"2024","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.numecd.2026.104950_bib30","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1210\/clinem\/dgab065","article-title":"Efficacy and safety of dulaglutide in older patients: a post hoc analysis of the REWIND trial","volume":"106","author":"Riddle","year":"2021","journal-title":"J Clin Endocrinol Metabol"},{"issue":"24","key":"10.1016\/j.numecd.2026.104950_bib31","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1093\/eurheartj\/ehz809","article-title":"Effect of alirocumab on cardiovascular outcomes after acute coronary syndromes according to age: an ODYSSEY OUTCOMES trial analysis","volume":"41","author":"Sinnaeve","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.numecd.2026.104950_bib32","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.clnu.2025.03.016","article-title":"A comprehensive comparison of two commonly used BMI thresholds for non-communicable diseases and multimorbidity in the Chinese population","volume":"48","author":"Fan","year":"2025","journal-title":"Clin Nutr"},{"key":"10.1016\/j.numecd.2026.104950_bib33","first-page":"253","article-title":"Obesity: preventing and managing the global epidemic. Report of a WHO consultation","volume":"894","year":"2000","journal-title":"World Health Organization Tech Rep Ser"},{"issue":"34","key":"10.1016\/j.numecd.2026.104950_bib34","doi-asserted-by":"crossref","first-page":"3258","DOI":"10.1093\/eurheartj\/ehab705","article-title":"Elevated remnant cholesterol increases the risk of peripheral artery disease, myocardial infarction, and ischaemic stroke: a cohort-based study","volume":"43","author":"Wadstrom","year":"2022","journal-title":"Eur Heart J"},{"issue":"19","key":"10.1016\/j.numecd.2026.104950_bib35","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.1016\/j.jacc.2025.11.016","article-title":"2026 ACC\/AHA\/AACVPR\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of dyslipidemia: a report of the American college of cardiology\/american heart association joint committee on clinical practice guidelines","volume":"87","author":"Blumenthal","year":"2026","journal-title":"J Am Coll Cardiol"},{"issue":"16","key":"10.1016\/j.numecd.2026.104950_bib36","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","article-title":"Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol","volume":"382","author":"Ray","year":"2020","journal-title":"N Engl J Med"},{"issue":"48","key":"10.1016\/j.numecd.2026.104950_bib37","doi-asserted-by":"crossref","first-page":"5047","DOI":"10.1093\/eurheartj\/ehac615","article-title":"Effect of inclisiran on lipids in primary prevention: the ORION-11 trial","volume":"43","author":"Ray","year":"2022","journal-title":"Eur Heart J"},{"issue":"16","key":"10.1016\/j.numecd.2026.104950_bib38","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1016\/j.jacc.2023.02.018","article-title":"Phase 2b randomized trial of the oral PCSK9 inhibitor MK-0616","volume":"81","author":"Ballantyne","year":"2023","journal-title":"J Am Coll Cardiol"},{"issue":"13","key":"10.1016\/j.numecd.2026.104950_bib39","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1001\/jama.285.13.1711","article-title":"Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial","volume":"285","author":"Schwartz","year":"2001","journal-title":"JAMA"},{"issue":"18","key":"10.1016\/j.numecd.2026.104950_bib40","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1001\/jama.2022.5218","article-title":"Effect of alirocumab added to high-intensity statin therapy on coronary atherosclerosis in patients with acute myocardial infarction","volume":"327","author":"R\u00e4ber","year":"2022","journal-title":"JAMA"},{"issue":"22","key":"10.1016\/j.numecd.2026.104950_bib41","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.numecd.2026.104950_bib42","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/j.amjcard.2017.01.008","article-title":"Usefulness of non\u2013high-density lipoprotein cholesterol as a predictor of cardiovascular disease mortality in men in 22-year follow-up","volume":"119","author":"Harari","year":"2017","journal-title":"Am J Cardiol"},{"issue":"7810","key":"10.1016\/j.numecd.2026.104950_bib43","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41586-020-2338-1","article-title":"Repositioning of the global epicentre of non-optimal cholesterol","volume":"582","author":"Taddei","year":"2020","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.numecd.2026.104950_bib44","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s12944-024-02078-0","article-title":"The effect of lipid-lowering therapy on lipid-related residual risk factors: a prospective study","volume":"23","author":"Li","year":"2024","journal-title":"Lipids Health Dis"},{"issue":"10263","key":"10.1016\/j.numecd.2026.104950_bib45","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/S0140-6736(20)32332-1","article-title":"Efficacy and safety of lowering LDL cholesterol in older patients: a systematic review and meta-analysis of randomised controlled trials","volume":"396","author":"Gencer","year":"2020","journal-title":"Lancet"},{"issue":"14","key":"10.1016\/j.numecd.2026.104950_bib46","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa050461","article-title":"Intensive lipid lowering with atorvastatin in patients with stable coronary disease","volume":"352","author":"Larosa","year":"2005","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.numecd.2026.104950_bib47","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1161\/CIRCULATIONAHA.117.032615","article-title":"High-dose versus low-dose pitavastatin in Japanese patients with stable coronary artery disease (REAL-CAD)","volume":"137","author":"Taguchi","year":"2018","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.numecd.2026.104950_bib48","first-page":"939","volume":"11","author":"Krychtiuk","year":"2022","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"issue":"2","key":"10.1016\/j.numecd.2026.104950_bib49","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1093\/ehjcvp\/pvaf004","article-title":"Impact of a personalized, strike early and strong lipid-lowering approach on low-density lipoprotein-cholesterol levels and cardiovascular outcome in patients with acute myocardial infarction","volume":"11","author":"Patti","year":"2025","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"15","key":"10.1016\/j.numecd.2026.104950_bib50","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1093\/eurjpc\/zwae170","article-title":"Strike early-strike strong lipid-lowering strategy with proprotein convertase subtilisin\/kexin type 9 inhibitors in acute coronary syndrome patients: real-world evidence from the at-TARGET-IT registry","volume":"31","author":"Gargiulo","year":"2024","journal-title":"Eur J Prev Cardiol"},{"issue":"Supplement_L","key":"10.1016\/j.numecd.2026.104950_bib51","doi-asserted-by":"crossref","first-page":"L53","DOI":"10.1093\/eurheartj\/suaa135","article-title":"Lipoprotein(a) and PCSK9 inhibition: clinical evidence","volume":"22","author":"Ruscica","year":"2020","journal-title":"Eur Heart J Suppl"},{"issue":"12","key":"10.1016\/j.numecd.2026.104950_bib52","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1161\/CIRCULATIONAHA.118.037184","article-title":"Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk","volume":"139","author":"O Donoghue","year":"2019","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.numecd.2026.104950_bib53","article-title":"Impact of proprotein convertase subtilisin\/kexin type 9 inhibitors on lipoprotein(a)","volume":"4","author":"Rivera","year":"2025","journal-title":"JACC: Advances"},{"issue":"1","key":"10.1016\/j.numecd.2026.104950_bib54","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1186\/s13098-024-01516-4","article-title":"Predictive properties of novel anthropometric and biochemical indexes for prediction of cardiovascular risk","volume":"16","author":"Mansoori","year":"2024","journal-title":"Diabetol Metab Syndr"},{"issue":"1","key":"10.1016\/j.numecd.2026.104950_bib55","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s12944-022-01732-9","article-title":"Evaluating the use of novel atherogenicity indices and insulin resistance surrogate markers in predicting the risk of coronary artery disease: a case\u2012control investigation with comparison to traditional biomarkers","volume":"21","author":"Mahdavi-Roshan","year":"2022","journal-title":"Lipids Health Dis"},{"issue":"1","key":"10.1016\/j.numecd.2026.104950_bib56","doi-asserted-by":"crossref","DOI":"10.1002\/dmrr.3764","article-title":"Assessment of six surrogate insulin resistance indexes for predicting cardiometabolic multimorbidity incidence in Chinese middle\u2010aged and older populations: insights from the China health and retirement longitudinal study","volume":"40","author":"Xiao","year":"2024","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1016\/j.numecd.2026.104950_bib57","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ejim.2024.08.026","article-title":"Triglyceride glucose (TyG) index: a promising biomarker for diagnosis and treatment of different diseases","volume":"131","author":"Sun","year":"2025","journal-title":"Eur J Intern Med"},{"issue":"1","key":"10.1016\/j.numecd.2026.104950_bib58","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1186\/s12933-025-02910-6","article-title":"Effect of changes in the triglyceride-glucose index on atherogenic lipid profiles in coronary artery disease patients receiving lipid-lowering therapy: a prospective cohort study","volume":"24","author":"Li","year":"2025","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"10.1016\/j.numecd.2026.104950_bib59","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s12933-025-02585-z","article-title":"Does diabetes modify the triglyceride\u2013glucose index associated with cardiovascular events and mortality? A meta-analysis of 50 cohorts involving 7,239,790 participants","volume":"24","author":"Zhang","year":"2025","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"10.1016\/j.numecd.2026.104950_bib60","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s12933-025-02582-2","article-title":"Atherogenic index of plasma and coronary artery disease: a systematic review and meta-analysis of observational studies","volume":"24","author":"Assempoor","year":"2025","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"10.1016\/j.numecd.2026.104950_bib61","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s11883-024-01270-y","article-title":"Debate: lipid-lowering therapies and diabetes development","volume":"27","author":"Brandts","year":"2025","journal-title":"Curr Atheroscler Rep"},{"issue":"1","key":"10.1016\/j.numecd.2026.104950_bib62","doi-asserted-by":"crossref","first-page":"112","DOI":"10.4093\/dmj.2022.0402","article-title":"Comparative efficacy of rosuvastatin monotherapy and rosuvastatin\/ezetimibe combination therapy on insulin sensitivity and vascular inflammatory response in patients with type 2 diabetes mellitus","volume":"48","author":"Han","year":"2024","journal-title":"Diabetes Metab J"},{"issue":"11","key":"10.1016\/j.numecd.2026.104950_bib63","doi-asserted-by":"crossref","first-page":"512","DOI":"10.3390\/biomedicines8110512","article-title":"Effect of ezetimibe on glucose metabolism and inflammatory markers in adipose tissue","volume":"8","author":"Cho","year":"2020","journal-title":"Biomedicines"},{"issue":"1","key":"10.1016\/j.numecd.2026.104950_bib64","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s12933-023-02077-y","article-title":"Impact of PCSK9 inhibitors in glycaemic control and new-onset diabetes","volume":"23","author":"Gonz\u00e1lez-Lle\u00f3","year":"2024","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"10.1016\/j.numecd.2026.104950_bib65","article-title":"Relationship between plasma atherogenic index and thyroid function: evidence from NHANES 2007-2012","volume":"15","author":"Li","year":"2025","journal-title":"Sci Rep"},{"issue":"12","key":"10.1016\/j.numecd.2026.104950_bib66","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1016\/j.numecd.2023.08.019","article-title":"Impaired HDL-associated enzymes and proteins in children and adolescents with weight disorders and their association with novel cardiometabolic indexes","volume":"33","author":"Martin","year":"2023","journal-title":"Nutr Metabol Cardiovasc Dis : NMCD"},{"issue":"5","key":"10.1016\/j.numecd.2026.104950_bib67","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.amjcard.2019.12.006","article-title":"Meta-analysis of the relation of body mass index to cardiovascular outcomes in patients receiving intensive low-density lipoprotein cholesterol lowering therapy","volume":"125","author":"Khan","year":"2020","journal-title":"Am J Cardiol"},{"issue":"1","key":"10.1016\/j.numecd.2026.104950_bib68","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1186\/s40001-025-02431-8","article-title":"Lower body mass index is associated with the achievement of target LDL in patients using PCSK9 inhibitors in Taiwan","volume":"30","author":"Tu","year":"2025","journal-title":"Eur J Med Res"},{"key":"10.1016\/j.numecd.2026.104950_bib69","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacl.2025.06.018","article-title":"Decline in LDL-c control in patients with dyslipidemia treated with PCSK9-inhibitors: the role of obesity in LDL-c target achievement","author":"Formisano","year":"2025","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.numecd.2026.104950_bib70","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115281","article-title":"Pharmacokinetics of obese adults: not only an increase in weight","volume":"166","author":"Gouju","year":"2023","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.numecd.2026.104950_bib71","doi-asserted-by":"crossref","first-page":"e46","DOI":"10.5114\/amsad.2017.70502","article-title":"Effects of increased body weight and short-term weight loss on serum PCSK9 levels - a prospective pilot study","volume":"2","author":"Filippatos","year":"2017","journal-title":"Arch Med Sci Atheroscler Dis"},{"key":"10.1016\/j.numecd.2026.104950_bib72","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajpc.2020.100012","article-title":"Unusual responses to PCSK9 inhibitors in a clinical cohort utilizing a structured follow-up protocol","volume":"1","author":"Warden","year":"2020","journal-title":"Am J Prev Cardiol"},{"issue":"4","key":"10.1016\/j.numecd.2026.104950_bib73","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.diabet.2019.101120","article-title":"Alirocumab efficacy and safety by body mass index: a pooled analysis from 10 phase 3 ODYSSEY trials","volume":"46","author":"Tinahones","year":"2020","journal-title":"Diabetes Metab"},{"issue":"11","key":"10.1016\/j.numecd.2026.104950_bib74","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1093\/oxfordjournals.aje.a009758","article-title":"Confounding by indication: an example of variation in the use of epidemiologic terminology","volume":"149","author":"Salas","year":"1999","journal-title":"Am J Epidemiol"}],"container-title":["Nutrition, Metabolism and Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939475326004126?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939475326004126?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T20:32:48Z","timestamp":1787949168000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939475326004126"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":74,"alternative-id":["S0939475326004126"],"URL":"https:\/\/doi.org\/10.1016\/j.numecd.2026.104950","relation":{},"ISSN":["0939-4753"],"issn-type":[{"value":"0939-4753","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intensified lipid-lowering strategies and their effect on atherogenic and metabolic markers in coronary artery disease: a prospective cohort study","name":"articletitle","label":"Article Title"},{"value":"Nutrition, Metabolism and Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.numecd.2026.104950","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of The Italian Diabetes Society, the Italian Society for the Study of Atherosclerosis, the Italian Society of Human Nutrition and the Department of Clinical Medicine and Surgery, Federico II University.","name":"copyright","label":"Copyright"}],"article-number":"104950"}}